CeriBell (NASDAQ:CBLL) CTO Raymond Woo Sells 1,979 Shares

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 1,979 shares of CeriBell stock in a transaction on Friday, August 21st. The shares were sold at an average price of $24.02, for a total value of $47,535.58. Following the completion of the sale, the chief technology officer owned 194,729 shares in the company, valued at $4,677,390.58. This represents a 1.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Trading Up 0.0%

Shares of NASDAQ CBLL traded up $0.01 during mid-day trading on Tuesday, reaching $23.95. 243,381 shares of the company’s stock were exchanged, compared to its average volume of 457,237. The firm has a market capitalization of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $25.33. The company’s 50-day moving average is $19.77 and its 200-day moving average is $19.27.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The company had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. Analysts expect that CeriBell, Inc. will post -1.96 EPS for the current fiscal year.

Institutional Trading of CeriBell

Hedge funds have recently made changes to their positions in the business. Strs Ohio purchased a new position in shares of CeriBell in the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd grew its holdings in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in CeriBell during the 3rd quarter worth approximately $33,000. CWM LLC lifted its holdings in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares in the last quarter.

Analyst Upgrades and Downgrades

CBLL has been the subject of several research reports. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Canaccord Genuity Group upped their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Barclays upgraded CeriBell to a “neutral” rating in a research report on Tuesday, August 18th. Finally, BTIG Research lifted their price objective on CeriBell from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.